OGXI 2.09 Oncogenex Pharmaceuticals Inc $OGXI Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 20, 2014 at 11:39 AM

OGXI 2.09 Oncogenex Pharmaceuticals Inc $OGXI Hit a 52 week low of 2.08 Closing the day 10:42 at 2.09 -0.01 -0.48% With a day low of 2.08 and a total volume of 35,341.

OGXI Recent Posts: http://investorshangout.com/Oncogenex-Pharmac...GXI-54968/

OGXI Oncogenex Pharmaceuticals Inc Recent Headline News

OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference
CNW Group - Mon Nov 17, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 10:55 a.m. ET at the New York Palace Hotel in New York City. The presentation will include an overview of apatorsen Phase 2 development plans, as well as additional data from custirsen Phase 3 SYNERGY exploratory analyses.
OGXI: 2.07 (-0.03)

Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 302.05 (-1.56), ALNY: 89.21 (-0.36), ISIS: 51.59 (+1.53), OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05), RGLS: 15.59 (-0.67), GSK: 46.43 (+0.18), SNY: 46.98 (-1.11)

Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.30 (+0.02), PCYC: 138.53 (-0.07), CLDX: 20.94 (+2.21), INCY: 71.85 (+0.55), BIND: 7.78 (-0.62), CELG: 107.77 (+0.79), OMER: 21.48 (+0.51), VSTM: 8.74 (-0.07), GILD: 102.72 (+0.38), OGXI: 2.07 (-0.03), ANTH: 1.84 (-0.01), NVAX: 5.01 (+0.17)

OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 3:04AM CST

OGXI: 2.07 (-0.03)

More on OncoGenex Pharmaceuticals Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:32PM CDT

OGXI: 2.07 (-0.03)

OncoGenex Pharmaceuticals beats by $0.14, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:34PM CDT

OGXI: 2.07 (-0.03)

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
CNW Group - Thu Oct 30, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results.
OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)

Some Of Soros' Stocks Surged Today, While Others Soured
at The Street - Wed Oct 29, 3:31PM CDT
OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), MCG Capital Corp (NASDAQ:MCGC) and Doral Financial Corp. (NYSE

RL) made noteworthy gains on the market this Wednesday. In the red today are Cal Dive In...
OGXI: 2.07 (-0.03), MCGC: 3.69 (unch), INVN: 15.42 (+0.28), DRL: 5.35 (+0.09), ARCP: 9.09 (+0.32)

OncoGenex reports on October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:27AM CDT

OGXI: 2.07 (-0.03)

OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014
PR Newswire - Thu Oct 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2014 financial results will be released on Thursday, October 30, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update.
OGXI: 2.07 (-0.03)

OncoGenex's Phase III Prostate Cancer Study Fully Enrolled - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:11PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) has finished enrolling patients in a phase III study (AFFINITY) on custirsen for metastatic castrate-resistant prostate cancer.
LCI: 47.02 (+0.18), ENDP: 69.30 (+0.29), OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)

5 Stocks Under $10 to Trade for Breakouts
at The Street - Thu Sep 18, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
NLST: 0.78 (-0.02), ANY: 8.00 (-0.39), OGXI: 2.07 (-0.03), GLYC: 8.19 (+0.41)

OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer
PR Newswire - Tue Sep 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the Phase 3 AFFINITY trial.
OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)

4 Under-$10 Biotech Stocks in Breakout Territory
at The Street - Wed Aug 27, 6:00AM CDT
These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.
OGXI: 2.07 (-0.03), ARTX: 2.30 (+0.06), CYTR: 2.57 (-0.06), CNCE: 12.74 (-0.07)

OncoGenex's Custirsen Passes First Interim Futility Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:40PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that the IDMC has recommended the continuation of the phase III ENSPIRIT study on custirsen for lung cancer.
ENDP: 69.30 (+0.29), OGXI: 2.07 (-0.03), UTHR: 128.79 (+0.79), TEVA: 57.30 (+0.05)

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer
PR Newswire - Thu Aug 21, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC) based upon completion of the first interim futility analysis.
OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sacrifice Unending: 9/11's Lingering Health Toll

The Unseen Toll of 9/11 on the Firefighter Community Two and a half decades since that fateful morning of September 11, 2001, we're staring at a grim reality. The heroic souls of the New York City Fire Department (FDNY)—those who ran toward peril when others ran away—are still paying the price. Incredibly, more than 400 FDNY members have succumbed to World Trade...

ABC Honors 2026 Spirit of the Heart Leaders

Celebrating Champions of Cardiovascular Health In a world where accolades often feel as cold as the stock market after a crash, it’s heartening to see genuine recognition for those who are making actual, lasting impact. On October 3, 2026, the Association of Black Cardiologists (ABC) will hold its annual Spirit of the Heart Awards at none other than Cipriani Wall...

Cap Juluca: Caribbean Luxury Redefined on Maundays Bay

The Tranquil Call of Maundays Bay Find me dipping my toes in the sands of Maundays Bay come October 10, 2026, and you'll understand why this slice of Anguilla stakes its claim to being the best beach on the globe. Cap Juluca, that crown jewel of Caribbean luxury, swings open its doors once more, promising indulgence framed by turquoise waters and the soft whisper of white...

Aflac's $200M Milestone in Cancer Charity Support

Pioneering Efforts Across Decades Here’s an effort that bucks the usual corporate talk. Aflac, the supplemental insurance giant, isn’t just mumbling about its mission; it's doing the heavy lifting in the fight against childhood cancer and blood disorders. With over $200 million in contributions poured into the cause over more than 30 years, they're putting the capital...

CUBEX Lights Up Veterinary Care with Mini Essential

Inventory Woes? Meet Mini Essential If you’ve ever worked in or around veterinary hospitals, you know the old-school headaches of managing controlled substances. Picture this: piles of paper logs, end-of-shift recounting, and inevitable discrepancies that rear their ugly heads long after closing time. Enter CUBEX, shaking things up with their latest launch, Mini...

LeoLabs and SciTec Partner for $93.7M Space Force Deal

LeoLabs and SciTec Join Forces for Space Dominance The space race ain't just about rockets blasting off anymore. It's about making sure we've got eyes everywhere, even on the back of our heads, so to speak. Enter LeoLabs teaming up with SciTec to help the U.S. Space Force upgrade their radar systems to something out of a sci-fi flick, armed with a $93.7 million contract...

Cove Capital Secures $9.96M for Debt-Free Logistics DST

Unpacking Cove Capital's Latest Victory Cove Capital Investments has pulled off another coup, raising a hefty $9,964,510 for its Cove Essential Net Lease Industrial 108 DST. It's a Regulation D, Rule 506(c) offering, now fully subscribed, spotlighting a debt-free investment ethos and a rock-solid logistics site in Anchorage, Alaska. Strategic Facility Anchoring Investment...

Sandbox VR Expands to Melbourne, Betting on Immersive Fun

Sandbox VR Ventures into Melbourne's Heart Every now and then, a venture takes its ambitions and rolls the dice on a prime location. Sandbox VR is swaggering into Melbourne's bustling Central Business District, fresh out of its success on the Gold Coast. Opening this Melbourne venue on September 14 marks a significant leap in the company's Aussie expansion—a bold nod to...

Tampa General’s Innovation Excellence Earns No. 20 Spot

A Bold Leap into Innovation at Tampa General There's a heck of a lot going on down in Tampa that's worth more than just a golf clap. Tampa General Hospital (TGH) just snagged the 20th spot on Fast Company's Best Workplaces for Innovators list, and let me tell you, that’s no small feat amidst the heavy hitters in verticals like biotech and consumer goods. It takes guts...

Shareholder Rights in Focus: Examining Key Buyouts

Shareholder Concerns Rise Amid Corporate Buyouts The stakes are high for the shareholders of Distribution Solutions Group, Eagle Financial Services, Safety Insurance Group, and Utz Brands as their companies face potential buyouts. Let's chew over what's on the table: the sweet deals insiders might score and the legal maneuvers in play. Halper Sadeh LLC, a heavy-hitting...